Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

Ruiying Kang,1 Yan He,1 Yuxiang Yan,1 Zhiwu Li,2 Yeqing Wu,3 Xiaojuan Guo,4 Zhigang Liang,5 Jun Jiang2 1Department of Epidemiology and Biostatics, School of Public Health, Capital Medical University, Beijing, People’s Republic of China; 2Fengtai Nanyuan Hospital of Beijing, Beijing, Peopl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kang RY, He Y, Yan YX, Li ZW, Wu YQ, Guo XJ, Liang ZG, Jiang J
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/6754a00c71ac4946a55bc7dfb6f478d7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6754a00c71ac4946a55bc7dfb6f478d7
record_format dspace
spelling oai:doaj.org-article:6754a00c71ac4946a55bc7dfb6f478d72021-12-02T04:11:32ZComparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial1178-2021https://doaj.org/article/6754a00c71ac4946a55bc7dfb6f478d72015-05-01T00:00:00Zhttp://www.dovepress.com/comparison-of-paroxetine-and-agomelatine-in-depressed-type-2-diabetes--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Ruiying Kang,1 Yan He,1 Yuxiang Yan,1 Zhiwu Li,2 Yeqing Wu,3 Xiaojuan Guo,4 Zhigang Liang,5 Jun Jiang2 1Department of Epidemiology and Biostatics, School of Public Health, Capital Medical University, Beijing, People’s Republic of China; 2Fengtai Nanyuan Hospital of Beijing, Beijing, People’s Republic of China; 3Fengtai District Community Health Center, Beijing, People’s Republic of China; 4Department of Preventive Medicine, School of Environmental and Public Health, Wenzhou Medical University, Wenzhou, People’s Republic of China; 5Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China Background: Comorbid depression/anxiety in type 2 diabetes mellitus (DM) patients is highly prevalent, affecting both diabetes control and quality of life. However, the best treating method for depression/anxiety in type 2 DM patients is still unclear. This study was conducted to compare the efficacy of paroxetine and agomelatine on depression/anxiety and metabolic control of type 2 DM patients.Methods: A total of 116 depressed, type 2 DM patients were recruited for 12 weeks treatment. Patients were randomly assigned to receive either paroxetine or agomelatine. Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were used to assess depression and anxiety, respectively. Hemoglobin A1c, fasting plasma glucose, and body mass index were assessed at baseline and at the end of the trial.Results: At the end of the trial, there were 34 (60.7%) responders and 22 (39.3%) remissions in paroxetine group; and 38 (63.3%) responders and 26 (43.3%) remissions in agomelatine group. Compared to paroxetine group, lower depression scores were observed in agomelatine group. Fasting plasma glucose and body mass index were not significantly different after 12 weeks treatment between the two groups, but agomelatine group had a significantly lower final hemoglobin A1c level compared to paroxetine group. The two antidepressants had comparable acceptability.Conclusion: These results showed that compared to paroxetine, agomelatine might have some advantages in treating symptoms of depression/anxiety and glycemic control in depressed type 2 DM patients. The clinical applicability of agomelatine shows greater promise and should be explored further. Limited by the relatively small samples, future studies are needed to verify and support our findings. Keywords: paroxetine, agomelatine, depression, diabetes mellitusKang RYHe YYan YXLi ZWWu YQGuo XJLiang ZGJiang JDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 1307-1311 (2015)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Kang RY
He Y
Yan YX
Li ZW
Wu YQ
Guo XJ
Liang ZG
Jiang J
Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
description Ruiying Kang,1 Yan He,1 Yuxiang Yan,1 Zhiwu Li,2 Yeqing Wu,3 Xiaojuan Guo,4 Zhigang Liang,5 Jun Jiang2 1Department of Epidemiology and Biostatics, School of Public Health, Capital Medical University, Beijing, People’s Republic of China; 2Fengtai Nanyuan Hospital of Beijing, Beijing, People’s Republic of China; 3Fengtai District Community Health Center, Beijing, People’s Republic of China; 4Department of Preventive Medicine, School of Environmental and Public Health, Wenzhou Medical University, Wenzhou, People’s Republic of China; 5Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China Background: Comorbid depression/anxiety in type 2 diabetes mellitus (DM) patients is highly prevalent, affecting both diabetes control and quality of life. However, the best treating method for depression/anxiety in type 2 DM patients is still unclear. This study was conducted to compare the efficacy of paroxetine and agomelatine on depression/anxiety and metabolic control of type 2 DM patients.Methods: A total of 116 depressed, type 2 DM patients were recruited for 12 weeks treatment. Patients were randomly assigned to receive either paroxetine or agomelatine. Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were used to assess depression and anxiety, respectively. Hemoglobin A1c, fasting plasma glucose, and body mass index were assessed at baseline and at the end of the trial.Results: At the end of the trial, there were 34 (60.7%) responders and 22 (39.3%) remissions in paroxetine group; and 38 (63.3%) responders and 26 (43.3%) remissions in agomelatine group. Compared to paroxetine group, lower depression scores were observed in agomelatine group. Fasting plasma glucose and body mass index were not significantly different after 12 weeks treatment between the two groups, but agomelatine group had a significantly lower final hemoglobin A1c level compared to paroxetine group. The two antidepressants had comparable acceptability.Conclusion: These results showed that compared to paroxetine, agomelatine might have some advantages in treating symptoms of depression/anxiety and glycemic control in depressed type 2 DM patients. The clinical applicability of agomelatine shows greater promise and should be explored further. Limited by the relatively small samples, future studies are needed to verify and support our findings. Keywords: paroxetine, agomelatine, depression, diabetes mellitus
format article
author Kang RY
He Y
Yan YX
Li ZW
Wu YQ
Guo XJ
Liang ZG
Jiang J
author_facet Kang RY
He Y
Yan YX
Li ZW
Wu YQ
Guo XJ
Liang ZG
Jiang J
author_sort Kang RY
title Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
title_short Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
title_full Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
title_fullStr Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
title_full_unstemmed Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
title_sort comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/6754a00c71ac4946a55bc7dfb6f478d7
work_keys_str_mv AT kangry comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
AT hey comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
AT yanyx comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
AT lizw comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
AT wuyq comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
AT guoxj comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
AT liangzg comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
AT jiangj comparisonofparoxetineandagomelatineindepressedtype2diabetesmellituspatientsanbspdoubleblindrandomizedclinicaltrial
_version_ 1718401374212849664

Ejemplares similares